Our first NRT product innovation
We’re proud to see our hard work paying off, with the first of our innovative nicotine inhalers having recently received approval as a medical device in the European Union.
This carefully conceptualised and developed NRT product, ENHALE, has been designed to help adult smokers to quit smoking by effectively alleviating nicotine withdrawal symptoms.
Using state-of-the-art technology linking the consumer to their treatment, ENHALE is undergoing regulatory approval.
We have been working hard to develop
The next generation of NRT products
Our specialists have been diligently focused on the development of the next generation of safer NRT products. Our emphasis has been on developing inhaler devices that can make a real change to the smoking paradigm and reimagine how smokers consume nicotine.
ENHALE, the first in our pipeline of medical developments, has been CE marked as a medical device in the European Union under the Medical Devices Directive and is currently in development for clinical studies in 2021 to support its marketing authorisation within Europe. Extensive research into nicotine delivery, stability and aerosol science has enabled cutting-edge developments in nicotine inhaler devices for a truly safe and effective way to deliver nicotine.
- Lower cost of goods
- Precise nicotine dose
- No thermal degredants
- Intuitive use
- Sate-of-the-art safety